Johnson & Johnson (NYSE:JNJ) Stake Decreased by Apollon Financial LLC

Apollon Financial LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 6.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,081 shares of the company’s stock after selling 133 shares during the period. Apollon Financial LLC’s holdings in Johnson & Johnson were worth $301,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. IFS Advisors LLC raised its holdings in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after purchasing an additional 100 shares in the last quarter. Highline Wealth Partners LLC bought a new position in shares of Johnson & Johnson in the third quarter valued at $31,000. RPg Family Wealth Advisory LLC bought a new position in shares of Johnson & Johnson in the third quarter valued at $35,000. Bay Harbor Wealth Management LLC bought a new position in shares of Johnson & Johnson in the fourth quarter valued at $32,000. Finally, Mowery & Schoenfeld Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after buying an additional 91 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the topic of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 16th. Citigroup lowered their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Guggenheim lifted their price objective on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research report on Monday, February 3rd. Stifel Nicolaus lowered their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research report on Thursday, January 23rd. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $170.67.

Johnson & Johnson Stock Up 1.3 %

JNJ stock opened at $156.18 on Wednesday. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The company has a fifty day simple moving average of $147.40 and a 200 day simple moving average of $156.04. The firm has a market cap of $376.02 billion, a PE ratio of 23.49, a PEG ratio of 2.46 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same quarter in the previous year, the business earned $2.29 EPS. Johnson & Johnson’s quarterly revenue was up 5.3% compared to the same quarter last year. Sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.18%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is 74.59%.

Insiders Place Their Bets

In other news, Director Mark A. Weinberger bought 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.